- Home
- ANVS vs LGVN Comparison
ANVS vs LGVN Comparison
Compare ANVS & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- LGVN
- Stock Information
- Founded
- ANVS 2008
- LGVN 2014
- Country
- ANVS United States
- LGVN United States
- Employees
- ANVS N/A
- LGVN N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- ANVS Health Care
- LGVN Health Care
- Exchange
- ANVS Nasdaq
- LGVN Nasdaq
- Market Cap
- ANVS 24.2M
- LGVN 27.6M
- IPO Year
- ANVS 2020
- LGVN 2021
- Fundamental
- Price
- ANVS $1.55
- LGVN $1.32
- Analyst Decision
- ANVS Strong Buy
- LGVN Strong Buy
- Analyst Count
- ANVS 4
- LGVN 3
- Target Price
- ANVS $40.67
- LGVN $8.67
- AVG Volume (30 Days)
- ANVS 459.6K
- LGVN 106.7K
- Earning Date
- ANVS 05-20-2025
- LGVN 05-08-2025
- Dividend Yield
- ANVS N/A
- LGVN N/A
- EPS Growth
- ANVS N/A
- LGVN N/A
- EPS
- ANVS N/A
- LGVN N/A
- Revenue
- ANVS N/A
- LGVN $2,392,000.00
- Revenue This Year
- ANVS N/A
- LGVN $1.30
- Revenue Next Year
- ANVS N/A
- LGVN $19.15
- P/E Ratio
- ANVS N/A
- LGVN N/A
- Revenue Growth
- ANVS N/A
- LGVN 237.38
- 52 Week Low
- ANVS $1.11
- LGVN $0.77
- 52 Week High
- ANVS $17.88
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- ANVS 56.90
- LGVN 41.63
- Support Level
- ANVS $1.42
- LGVN $1.48
- Resistance Level
- ANVS $1.75
- LGVN $1.77
- Average True Range (ATR)
- ANVS 0.15
- LGVN 0.12
- MACD
- ANVS 0.04
- LGVN -0.02
- Stochastic Oscillator
- ANVS 84.62
- LGVN 2.33
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.